Literature DB >> 15750033

In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide.

Sara Lopez1, Corinne Hackbarth, Gabriella Romanò, Joaquim Trias, Daniela Jabes, Beth P Goldstein.   

Abstract

OBJECTIVES: Dalbavancin is a novel, semi-synthetic glycopeptide antibiotic. The aim of this study was to further explore its activity against staphylococci.
METHODS: The bactericidal activity of dalbavancin was studied using MBC and time-kill methods. The potential for resistance to dalbavancin was examined using single-step and serial-passage experiments.
RESULTS: Dalbavancin was bactericidal against methicillin-susceptible and -resistant Staphylococcus aureus, in both the presence and absence of human serum. No resistance was seen with any isolate tested. After serial passage, bacterial populations were more homogeneous in their susceptibility to dalbavancin than to vancomycin or teicoplanin.
CONCLUSION: Dalbavancin is bactericidal for staphylococci. Resistance to this semi-synthetic glycopeptide is not readily developed in vitro.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750033     DOI: 10.1093/jac/dki007

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  19 in total

Review 1.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

2.  Bactericidal activity and resistance development profiling of dalbavancin.

Authors:  Beth P Goldstein; Deborah C Draghi; Daniel J Sheehan; Patricia Hogan; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

3.  Dalbavancin (zeven), a novel glycopeptide for resistant gram-positive organisms.

Authors:  Jennifer Colabella; Larisa Chagan
Journal:  P T       Date:  2008-01

4.  Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.

Authors:  Michael W Dunne; Sailaja Puttagunta; Craig R Sprenger; Chris Rubino; Scott Van Wart; James Baldassarre
Journal:  Antimicrob Agents Chemother       Date:  2015-01-05       Impact factor: 5.191

5.  Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.

Authors:  Douglas J Biedenbach; James E Ross; Thomas R Fritsche; Helio S Sader; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2007-01-10       Impact factor: 5.948

6.  Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections.

Authors:  Pier Giorgio Cojutti; Matteo Rinaldi; Eleonora Zamparini; Nicolò Rossi; Sara Tedeschi; Matteo Conti; Federico Pea; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2021-03-01       Impact factor: 5.191

7.  In Vitro Study To Evaluate the Bioactivity of Freezing a Heparin-Based Dalbavancin Lock Solution.

Authors:  Marta Rubia; Andrea Cordero; María Jesús Pérez-Granda; Emilia Cercenado; Cristina Pascual; Patricia Muñoz; María Guembe
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

Review 8.  Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

Review 9.  Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

10.  Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.

Authors:  Adam Belley; David Lalonde Seguin; Francis Arhin; Greg Moeck
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.